Published in Curr Oncol on February 01, 2007
Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol (2005) 5.80
Monoclonal antibody therapy of cancer. Nat Biotechnol (2005) 5.79
Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol (2006) 2.79
Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol (2006) 2.57
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol (2005) 2.55
Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol (2005) 1.83
Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin (2006) 1.50
Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med (2005) 1.49
Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res (2005) 1.49
The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res (2004) 1.22
Current status of therapy of solid tumors. J Nucl Med (2005) 1.14
A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res (2002) 1.14
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol (2006) 1.12
Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol (2005) 1.10
Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer (2002) 1.09
Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer (2002) 1.06
Advances in radioimmunotherapy in the age of molecular engineering and pretargeting. Cancer Invest (2006) 1.02
Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging (2006) 1.02
Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Cancer (2000) 0.98
Monoclonal antibody therapy for B-cell malignancies. Semin Oncol (2006) 0.97
Targeted radionuclide therapy for solid tumors: an overview. Int J Radiat Oncol Biol Phys (2006) 0.96
Radioimmunotherapy of non-Hodgkin's lymphomas. Curr Drug Targets (2006) 0.93
Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Best Pract Res Clin Haematol (2006) 0.89
Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res (1987) 0.86
Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisal. Expert Rev Clin Immunol (2005) 0.84
Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies. Technol Cancer Res Treat (2005) 0.82
Adjuvant and combined radioimmunotherapy: problems and prospects on the road to Minerva. J Nucl Med (2006) 0.81
Can occult metastases be treated by radioimmunotherapy? Cancer (1997) 0.79
Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys (2006) 0.79